Differences in metabolic side-effects of typical and atypical antipsychotic treatment in elderly individuals with long-term schizophrenia

Boris Finkel, Craig Goodman, Yuval Melamed, Mahmud Naser, Piter Andreyev, Yehoshua Segev, Avi Bleich

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To examine metabolic side-effects of year-long treatment with clozapine, risperidone, quetiapine, or olanzapine in comparison to treatment with haloperidol or perphenazine, among elderly individuals with long-term schizophrenia. Participants and Methods: In a retrospective chart review, clinical records of 228 psychiatric inpatients with persistent schizophrenia were examined to determine any differences in metabolic side-effects of typical versus atypical antipsychotic treatment. Results: There were no significant differences with respect to body mass index, body weight, blood glucose, and serum triglyceride, cholesterol, B12, and folic acid levels. Conclusions: Elderly psychogeriatric patients may be less susceptible to the metabolic side-effects associated with atypical antipsychotic agents than younger populations. This finding warrants further investigation in prospective randomised controlled trials.

Original languageEnglish
Pages (from-to)103-106
Number of pages4
JournalHong Kong Journal of Psychiatry
Volume19
Issue number3
StatePublished - Sep 2009

Keywords

  • Aged
  • Antipsychotic agents
  • Schizophrenia

Fingerprint

Dive into the research topics of 'Differences in metabolic side-effects of typical and atypical antipsychotic treatment in elderly individuals with long-term schizophrenia'. Together they form a unique fingerprint.

Cite this